AIDS Drug Assistance Program (ADAP)
Medical Advisory Committee (MAC)
The ADAP MAC consists of HIV-specialized physician/s, pharmacist/s, psychiatrist/s, treatment advocacy representative/s, and affected community member/s. The primary role of the MAC is to review the program formulary, evaluate available HIV/AIDS related drugs, in addition to medications used in the treatment of opportunistic infections, and make recommendations for changes to the program formulary.
The MAC developed a vision statement for ADAP, which continues to guide the committee in its review of drugs for inclusion in the formulary:
"ADAP will make available, in an effective and timely manner to people living with HIV, pharmaceutical and other treatments which are reliably expected to increase survival, reduce mortality, and improve quality of life."
The California Department of Public Health (CDPH) met with the ADAP MAC on July 20, 2022 and discussed the vulnerability of people living with HIV to Monkeypox (MPX) infection and complications. Individuals at risk of acquiring HIV (and eligible for HIV pre-exposure prophylaxis [PrEP]) were also discussed as a population with increased risk for MPX infection. The ADAP MAC unanimously agreed that access to MPX vaccination with Jynneos should be prioritized for people with HIV and people eligible for HIV PrEP. This statement is consistent with CDPHās expansion of MPX vaccine eligibility on October 4, 2022.